High dose therapy and stem cell transplantation: A new approach in tumor therapy;Hochdosistherapie und Stammzelltransplantation. Ein neuer Weg in der Tumortherapie

Internist

Volumn 38, Issue 11, 1997, Pages 1045-1049

  Kanz, L ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR;

CELL TRANSPLANTATION; HUMAN; LEUKEMIA; REVIEW; STEM CELL;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; NEOPLASMS; TREATMENT OUTCOME;

EID: 0030722335     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050115     Document Type: Review

References (17)

1. Frei E III, Canellos G (1980) Dose: a critical factor in cancer chemotherapy. Am J Med 69:585-594
2. Hryniuk W, Bush H (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281-1288
3. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD (1988) Granulocytemacrophage colony-stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1:1194-1198
4. Sheridan WP, Begley CG, Juttner CA et al (1992) Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose-the-rapy. Lancet 339:640-644
5. Sheridian WP, Begley GC, To LB et al (1994) Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high dose chemotherapy for lymphoid malignancies. Bone Marrow Transplantation 14:105-111
6. Schmitz N, Dreger P, Suttorp M et al (1995) Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 85:1666-1672
7. Bensinger WI, Weaver CH, Appelbaum FR et al (1995) Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor (rh-G-CSF). Blood 85:655-658
8. Shpall EJ, Jones RB (1994) Release of tumor cells from bone marrow. Blood 83:623-625
9. Moss TJ, Sanders DG, Lasky LC et al (1990) Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells. Blood 76:1879-1883
10. Ross AA, Cooper BW, Lazarus HM et al (1993) Detection and viability of tumour cells lin peripheral blood stem cell collections from breas cancer patients using immunocytochemical and clonogenic assay techniques. Blood 82:2605-2610
11. Brenner MK, Rill DR, Moen RC et al (1993) Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 34:85-86
12. Rill RD, Santan VM, Roberts WM et al (1994) Direct demonstration that autologous bone marrow transplantation for solid tumours can return a multiplicity of tumourrigenic cells. Blood 84:380-383
13. Brugger W, Bross KJ, Glatt M et al (1994) Mobilization of tumour cells and haemato-poietic progenitor cells into peripheral blood of patients with solid tumours. Blood 83:636-640
14. Kanz L, Subklewe M, Brugger W (1996) Treatment of solid tumors with high-dose chemotherapy requiring cellular support. In: Morstyn G, Sheridan W (eds) Cell Therapy: Stem cell transplantations, gene therapy, and cellular immunotherapy. Cambridge University Press, p 312-336
15. Sallusto F, Lanzavecchia A (1994) Efficient presentationl of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colo- ny-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J Exp Med 179:1109-1118
16. + hematopoietic progenitor cells in cancer patients. Eur J Immunol 26:595
17. + bone marrow progenitors that are expanded by c-kit ligand and yield pure dendritic cell colonies in the presence of GM-CSF and TNFa. J Exp Med 182:1111-1120